MedTrace Logo

Immunomodulatory Therapy & VSA

NCT06696807 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2024-11-20

No results posted yet for this study

Summary

Vasospastic angina (VSA) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion. Although vasodilator therapy is widely used and significantly alleviates VSA symptoms, it has not led to notable improvements in the prognosis of patients with VSA. Recent studies have suggested that inflammation plays a crucial role in VSA. This study aimed to evaluate the potential effectiveness of immunomodulatory therapy for improving patient prognosis.

Conditions

  • Vasospastic Angina

Interventions

DRUG

glucocorticosteroids and/or intravenous immunoglobulin

methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day

Sponsors & Collaborators

  • Dao Wen Wang

    lead OTHER

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2024-04-01
Completion
2024-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696807 on ClinicalTrials.gov